Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study

被引：0

作者：

Coveler, Andrew L.

Reilley, Matthew

Zalupski, Mark

Macarulla, Teresa

Fountzilas, Christos

Castanon Alvarez, Eduardo

Nagrial, Adnan

Volodymyrivna Uboha, Nataliya

Frentzas, Sophia

Overman, Michael J.

Noonan, Anne M.

Messersmith, Wells A.

Pavlakis, Nick

Mettu, Niharika B.

Smith, Paul

Murtomaki, Elina

Bragulat, Veronique

Cooper, Zachary A.

Kumar, Rakesh

Spigel, David

机构：

[1] Fred Hutchinson Canc Ctr, Seattle, WA USA

[2] Univ Virginia, Ctr Comprehens Canc, Charlottesville, VA USA

[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[4] Hosp Univ Vall DHebron, Barcelona, Spain

[5] Roswell Pk Canc Inst, Buffalo, NY USA

[6] Clin Univ Navarra, Madrid, Spain

[7] Blacktown Hosp, Sydney, NSW, Australia

[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[9] Monash Hlth Monash Med Ctr, Clayton, Vic, Australia

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[12] Univ Colorado, Denver, CO USA

[13] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia

[14] Duke Univ, Med Ctr, Durham, NC USA

[15] AstraZeneca, Cambridge, England

[16] AstraZeneca, Gaithersburg, MD USA

[17] Sarah Cannon Res Inst, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[31] Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Antonia, Scott
Goldberg, Sarah B.
Balmanoukian, Ani
Chaft, Jamie E.
Sanborn, Rachel E.
Gupta, Ashok
Narwal, Rajesh
Steele, Keith
Gu, Yu
Karakunnel, Joyson J.
Rizvi, Naiyer A.
LANCET ONCOLOGY, 2016, 17 (03): : 299 - 308
[32] ARC-8: Phase 1/1b randomized study of quemliclustat plus gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.
Wainberg, Zev A.
Manji, Gulam Abbas
Bahary, Nathan
Ulahannan, Susanna Varkey
Pant, Shubham
Uboha, Nataliya Volodymyrivna
Oberstein, Paul Eliezer
Lu, Lawrence H.
Scott, Jennifer R.
Wu, Wilson
Rhee, Joon
Nuyten, Dimitry S. A.
O'Reilly, Eileen Mary
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 665 - 665
[33] A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.
Hilty, Bailey
Ruffolo, Luis I.
Belt, Brian A.
Byrne, Matthew
Dave, Yatee A.
Burchard, Paul R.
Fisher, Terrence Lee
Evans, Elizabeth E.
Mallow, Crystal L.
Boise, Megan
Zauderer, Maurice
Mulkerin, Daniel
Yeh, Jen Jen
Linehan, David
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS712 - TPS712
[34] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
Zhu, Xuelian
Cockrum, Paul
Shah, Bonny
Parzynski, Craig
Garawin, Tamer
Maxwell, Fiona
Surinach, Andy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205).
Lim, Kian-Huat
Spencer, Kristen Renee
Safyan, Rachael A.
Picozzi, Vincent J.
Varghese, Anna M.
Siolas, Despina
Perez, Kimberly
Clift, Sheena
Denis, Louis J.
Bhambhani, Vijeta
Hill, Stacey
Pachter, Jonathan A.
Pultar, Philippe
Hidalgo, Manuel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Phase 1b/2 trial of tucatinib plus trastuzumab plus /-chemotherapy or pembrolizumab in patients with metastatic HER2+GI cancers
Shitara, Kohei
Park, Haeseong
Bekaii-Saab, Tanios
Kim, Sunnie S.
Kamath, Suneel
Pishvaian, Michael J.
Chen, Christopher
Zhen, David B.
Mayor, Joal
Tan, Qianwen
Strickler, John H.
ANNALS OF ONCOLOGY, 2022, 33 : S502 - S502
[37] Comprehensive analysis of radiographic, clinical, and inflammatory markers demonstrating changes in lean muscle correlate with outcome in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT).
Ahn, Daniel H.
Ahn, Chul
Nagar, Veena
Noonan, Anne M.
Farren, Matthew
Lesinski, Gregory B.
Knopp, Michael V.
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[38] PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS
Banerjee, Susana
Oaknin, Ana
Sanchez-Simon, Inmaculada
Salgado, Alfonso Cortes
Patel, Sandip Pravin
Oza, Amit
Das, Mayukh
Kourtesis, Panagiotis
Ascierto, Maria Libera
Diamond, Jennifer R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A86 - A87
[39] Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment
Poplin, Elizabeth
Wasan, Harpreet
Rolfe, Lindsey
Raponi, Mitch
Ikdahl, Tone
Bondarenko, Ihor
Davidenko, Irina
Bondar, Volodymyr
Garin, August
Boeck, Stefan Hubert
Heinemann, Volker
Bassi, Claudio
Evans, T. R. Jeffry
Voong, Cynthia
Kaur, Paramjit
Isaacson, Jeffrey D.
Allen, Andrew R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX plus /- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma
Arnold, Dirk
Loghmani, Houra
Cheetham, Karol
Trauger, Richard
Heineman, Thomas Charles
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →